Quan-guang Zhang, MS, PhD (P.I.)
Professor of Neurology
Bachelor of Science, Biological Science (1998) - Anhui Normal University, Wuhu, China
Master of Science, Biochemistry & Molecular Biology (2003) - Xuzhou Medical University, Xuzhou, China
PhD, Neuroscience (2006) - University of Science & Technology of China, Hefei, China
Post-Doctoral Fellow (2008) - Medical College of Georgia, Augusta, GA
News
Dr. Zhang was selected as a 2024 Research Excellence Award Recipient at the LSU Health Shreveport Research Celebration on February 15, 2024.
A research paper on drug repurposing, specifically the use of clemastine to alleviate traumatic brain injury (TBI)-induced cognitive impairment, has been provisionally selected for the "Best Researcher Award" at the "International Research Awards on New Science Inventions."
DOD grant, Co-PI with Dr. Jordan. “Photobiomodulation Therapy Could be a Potential Treatment Strategy for Post-Traumatic Stress Disorder” Score: 1.8 (excellent), recommended for funding as an alternate.
The Institutional Review Board (IRB) at LSU Health Shreveport has granted approval to the Zhang lab for the human study protocol using expedited procedures. Title of research study: A survey of biomarkers in Stroke (STUDY00002490).
Objectives:
1.1 The primary purpose of this research study is to collect blood and data for the study of stroke.
1.2 Blood will be securely stored/banked in the investigator’s lab and may be kept for an indefinite amount of time.
1.3 This study aims to identify and validate blood biomarkers and/or clinical factors as predictors of disease onset, diagnosis, treatment decision, and outcomes for the purpose of stroke prevention, and treatment, as well as understanding disease etiopathology.
Congratulations to the Zhang lab for winning the Trainee Professional Development Award (TPDA), Society for Neuroscience (SFN) conference 2023: Photobiomodulation Treatment Inhibits Stroke-induced Cerebrovascular Senescence and Enhances Angiogenesis.
Dr. Zhang served as a Guest Editor for Frontiers in Physiology, overseeing the Research Topic titled "Preventive and Therapeutic Potential of Physical Exercise in Neurodegenerative Diseases" in 2023.
Zhang lab presented two posters on the Society for Neuroscience (SFN) - Washington, USA, Nov, 2023.
Dr. Zhang served as a Guest Editor for Frontiers in Sports and Active Living. Research Topic “Preventive and Therapeutic Potential of Physical Exercise in Neurodegenerative Diseases” 2023.
Dr. Zhang contributed as a member of the departmental promotion and tenure committee (2023). The committee's objective is to conduct a fair assessment of faculty members for appointments, promotions, and tenure.
Dr. Zhang served as a Guest Editor for Frontiers in Neurology. Research Topic “Photobiomodulation therapy for brain disorders”, 2023.
Dr. Zhang served as a Guest Editor for Frontiers in Cardiovascular Medicine. Research Topic “Role of Flavonoids in Cardiovascular Disease: from Bench to Bedside”, 2022-2023.
During 2022-2023, Dr. Zhang was invited to serve as a grant reviewer for prestigious organizations including the National Institutes of Health, American Heart Association, National/regional Science Center of Poland, Hong Kong, and Swiss, among others.
Zhang lab presented two posters on the Biomedical Research and Industry Day (BRAID), LSU Health, Shreveport, 2023.
Invited presentation by Dr. Zhang: Efficacy of Photobiomodulation Therapy in Regulating Synaptic Plasticity and Memory. April, 2023. Department of Toxicology & Cancer Biology, University of Kentucky College of Medicine.
Invited presentation by Dr. Zhang: Noninvasive Brain Stimulation for Brain Protection, Repair and Regeneration. Feb, 2022. Department of Pharmacology, Toxicology & Neuroscience. LSUHS.
Zhang lab presented a poster on the Biomedical Research and Industry Day (BRAID): Repetitive transcranial magnetic stimulation promotes stroke recovery by enhancing neurogenesis., LSU Health Shreveport. October, 2022.
As of 2022, the Zhang lab is equipped with a new "Remy laser system," emitting triple-wave radiation at wavelengths of 810±10nm, 915nm±10nm, and 1064±10nm. The system has received approval from the U.S. Food and Drug Administration (FDA). Recently, the Near-infrared II (NIR-II) photobiomodulation has been shown to augment endothelial nitric oxide bioavailability. NIR-II encompasses wavelengths from approximately 1000 to 1700 nanometers within the near-infrared (NIR) spectrum, often referred to as the second biological window. This range is widely recognized for its enhanced tissue penetration, reduced scattering, lower auto-fluorescence, and diminished absorption by water and hemoglobin. NIR-II's unique properties make it a valuable tool in diverse fields such as medicine, imaging, and materials science.
Dr. Zhang made a contribution to a book titled "Photobiomodulation in the Brain." The chapter, titled "Photobiomodulation in Photothrombotic Stroke," is featured in the paperback with ISBN 9780128153055 and eBook with ISBN 9780128153062.
Research
The primary goal of the Zhang lab is to advance non-invasive therapeutic approaches for safeguarding the brain against neurodegenerative conditions, particularly Alzheimer’s disease (AD) dementia and various neurological and psychiatric disorders. In pursuit of this critical goal, our ongoing investigations concentrate on assessing the efficacy of non-invasive approaches in both the "early preventive" phase for neuroprotection and the "late therapeutic" phase for repairing the injured brain beyond the therapeutic protection windows.
Our research centers on exploring the positive impacts of Photobiomodulation (PBM) Therapy, formerly known as Low-level laser (light) therapy (LLLT), utilizing Near-infrared (NIR) light to facilitate tissue repair. Additionally, we investigate pulsed electromagnetic field (PEMF) therapy and combinations that integrate aerobic exercise training.
To systematically assess these therapeutic strategies, we employ established animal models in our laboratory, including, but not limited to:
- Brain trauma models, covering Traumatic Brain Injury (TBI) and Repeated-closed Head Injury models.
- Cerebral ischemia models, including Global Brain Ischemia/Cardiac Arrest, Focal Brain Ischemia/Stroke, and neonatal Hypoxic-ischemic Encephalopathy (HIE).
- Mental disorder models, such as those related to Early Life Adversity, Post-Traumatic Stress Disorder (PTSD), and a depression-like animal model.
- Murine models specifically designed to emulate Alzheimer's Dementia.
By employing comprehensive translational approaches, we can systematically assess the effectiveness and applicability of non-invasive interventions across various pathological conditions. This substantially contributes to the progression of therapeutic strategies for brain protection and the repair of injuries. Our studies aim to uncover novel signaling pathways and factors associated with low-dose laser and electromagnetic therapy, offering insights into brain protection and neural regeneration in neurological diseases. This understanding holds the potential to pave the way for the development of new therapies with the prospect of translation to clinical applications.
We recognize that the ultimate goal of any therapeutic intervention is to enhance outcomes for neurological diseases. The Zhang lab is equipped with a dedicated behavioral room featuring various small animal testing apparatus. Utilizing multiple video cameras controlled by ANY-maze video tracking software (Stoelting Co., Wood Dale, IL), our lab proficiently conducts a diverse array of behavioral tests in experimental animals, encompassing but not limited to those outlined below.
Types of Tests
Rotarod Test: Measures motor coordination and balance.
Corner Test: Assesses sensorimotor integration and turning behavior.
Elevated Body Swing Test: Observes asymmetry in body swings after suspension, indicating motor deficits.
Cylinder Test: Evaluates forelimb asymmetry during exploratory behavior.
Ladder Dexterity Test: Assesses the animal's walking and traversal skills on a horizontal ladder with irregularly spaced rungs, demanding precise coordination and balance. It is designed to examine sensorimotor deficits, measured by counting foot faults on a grid.
Novel Object Recognition Test: Measures recognition memory for new objects.
Y-Maze Test: Evaluates spatial working memory and spontaneous alternation.
T-Maze Spontaneous Alternation Test: Assesses working memory and spatial cognition.
Contextual and Cued fear Conditioning Test: Evaluates associative fear learning and memory in rodent. It entails exposing animals to aversive stimuli, like mild foot shocks, in specific contexts (contextual fear conditioning), and associating a neutral stimulus (cue), such as a tone or light, with the aversive stimuli (cued fear conditioning). This test assesses the animals' ability to remember and respond to these associations, offering insights into their fear-related learning and memory processes.
Open Field Test: Measures general locomotor activity and anxiety-like behavior.
Sociability and Social Novelty Test: Measures an animal's social approach, preference for social interaction, and its ability to recognize and respond to novel social stimuli. The Social Recognition Test, on the other hand, focuses on evaluating social memory and recognition.
Barnes Maze Test: Assesses spatial learning and memory, similar to the Morris Water Maze. It involves a circular platform with multiple holes around the perimeter, one of which leads to an escape box. In the training trial testing stage, the rodent learns to navigate the maze using spatial cues to locate the escape box, thereby assessing its spatial memory and cognitive abilities. This evaluation involves measuring the escape latency (time taken to locate the recessed escape chamber) and tracking searching errors on the holes. In the subsequent Probe tests, after removing the escape chamber, we record the time spent in the target quadrant (quadrant occupancy) during a limited period, reflecting the animal's memory.
Forced Swimming Test: Measures behavioral despair and depressive-like responses in rodents.
Tail Suspension Test (TST): Evaluates behavioral despair and learned helplessness in mice by suspending them by their tails, inducing a temporary state of immobility in response to stress. It is commonly employed to assess the impact of potential antidepressant treatments.
Elevated Plus Maze: Assesses anxiety-related behavior in rodents by exploiting their natural aversion to open and elevated spaces.
Startle Test: Measures the startle response, which is an involuntary reaction to a sudden and intense sensory stimulus, typically a loud acoustic stimulus.
Our findings suggest that PBM has the potential to serve as a non-invasive treatment for preventing the occurrence of PTSD-like comorbidities when applied during early intervention windows, particularly during fear memory processing windows. However, the optimal PBM parameters for human treatment are still to be determined. Given the significant difference in thickness between human and rat skulls, further research is needed to refine and establish the most effective parameters for human applications. We demonstrated that PBM could potentially "protect" the consolidation process for contextual memory following traumatic events by: (a) increasing discriminability, (b) blocking reconsolidation, and (c) facilitating fear extinction. The potential underlying mechanism may lie in the PBM-enhanced ATP production and differentially regulated protein expression in the hippocampus, as partially displayed below. Publications related to this work include: (1). Transl Psychiatry. 2021 May 5;11(1):270. Link: https://pubmed.ncbi.nlm.nih.gov/33953158/ (2). Mol Psychiatry. 2021 Nov;26(11):6666-6679. Link: https://pubmed.ncbi.nlm.nih.gov/33859360/
Our findings suggest that theta-burst transcranial magnetic stimulation enhances stroke recovery through vascular protection and neovascularization. We emphasized the potent protective and restorative effects of repetitive transcranial magnetic stimulation (rTMS) on the microvasculature surrounding the infarcted area in a rat model of photothrombotic (PT) stroke. As depicted below, rTMS treatment effectively preserved blood-brain barrier (BBB) permeability in the peri-infarct cortical region induced by PT-stroke. Additionally, rTMS treatment attenuated excessive astrocyte-vasculature interactions and prompted the transition of astrocytic phenotypes from A1 to A2 in the peri-infarct region.
Publications
Selected Publications
- Zong XM, Huang Z, Kong F, Feng Y, Zhang Y, Zou P, Lin HW, Hess D, Zhang Q. Enhancing Myelination Ameliorates Cognitive Deficits Induced by Chronic Cerebral Hypoperfusion: the Effect of Clemastine in an Experimental Rat Model. Journal of Cerebral Blood Flow and Metabolism. 2025. In press.
- Mao L, Wang L, Huang Z, Switzer JA, Hess DC, Zhang Q. Perioperative neurocognitive disorders: Advances in molecular mechanisms and bioactive molecules. Ageing Research Reviews. 2025 Sep 4;112:102885.
- Huang Z, Zhang Y, Zou P, Zong X, Zhang Q Myelin dysfunction in aging and brain disorders: mechanisms and therapeutic opportunities. Mol Neurodegener. 2025 Jun 15;20(1):69.
- L Mao, L Wang, Z Huang, JK Chen, L Tucker, Zhang Q. Comprehensive insights into emerging advances in the Neurobiology of anorexia. Journal of Advanced Research. 2025 Apr 1:S2090-1232(25)00206-1.
- Y Feng, X Ma, X Zong, JD Jordan, CYC Wu, V Tesic, RHC Lee, Q Zhang. Clemastine enhances myelin formation in the striatum and medial prefrontal cortex and improves sociability in a neonatal rat hypoxic-ischemic model. Biomedicine & Pharmacotherapy 2025, 185, 117916.
- Huang Z, Xu P, Hess D, Zhang Q. Cellular senescence as a key contributor to secondary neurodegeneration in traumatic brain injury and stroke. Transl Neurodegener. 2024 Dec 12;13(1):61.
- Wang L, Mao LW, Huang Z, Switzer J, Hess D, Zhang Q. Photobiomodulation: shining a light on depression. Theranostics 2025; 15(2):362-383. doi:10.7150/thno.104502.
- Huang ZH, Hamblin M, Zhang Q. Photobiomodulation in experimental models of Alzheimer's disease: State-of-the-art and translational perspectives. Alzheimer's Research & Therapy. 16, 114 (2024).
- Huang ZH, Hamblin M, Zhang Q. Photobiomodulation in experimental models of Alzheimer's disease: State-of-the-art and translational perspectives. Alzheimer's Research & Therapy. 2024 May 21;16(1):114.
- Huang Z, Feng Y, Zhang Y, Ma X, Zong X, Jordan JD, Zhang Q. Enhancing axonal myelination: Clemastine attenuates cognitive impairment in a rat model of diffuse traumatic brain injury. Transl Res. 2024 Jun:268:40-50.
- Feng Y, Huang Z, Ma X, Zong X, Wu Y, Lee H, Lin H, Hamblin M, Zhang Q. Activation of Testosterone-Androgen Receptor Mediates Cerebrovascular Protection by Photobiomodulation Treatment in Photothrombosis-induced Stroke Rats. CNS Neuroscience & Therapeutics. 2024, Jan, In press.
- Huang Z, Jordan J. D., Zhang Q. Myelin pathology in Alzheimer's disease: potential therapeutic opportunities. Aging Dis. 2024 Apr 1;15(2):698-713.
- Huang Z, Jordan J. D., Zhang Q. Early Life Adversity as a Risk Factor for Cognitive Impairment and Alzheimer's Disease. Translational Neurodegeneration. 2023 May 12;12(1):25.
- Huang Z, Zhang Y, M Xa, Feng Y, Zong X, Jordan J. D., Zhang Q. Photobiomodulation attenuates oligodendrocyte dysfunction and prevents adverse neurological consequences in a rat model of early life adversity. Theranostics 2023; 13(3): 913-930.
- Y Feng, L Yang, X Ma, Z Huang, X Zong, CT Citadin, HW Lin, Q Zhang. Photobiomodulation treatment inhibits neurotoxic astrocytic polarization and protects neurons in in vitro and in vivo stroke models. Neurochem Int. 2023 Jan;162:105464.
- Feng W, Domeracki A, Park C, Shah S, Chhatbar PY, Pawar S, Chang C, Hsu PC, Richardson E, Hasan D, Sokhadze E, Zhang Q, Liu H. Revisiting Transcranial Light Stimulation as a Stroke Therapeutic-Hurdles and Opportunities. Transl Stroke Res. 2023 Dec;14(6):854-862.
- Yang L, Wu C, Li Y, Dong Y, Wu C, Lee R, Brann D, Lin H, Zhang Q. Long-term Exercise Pre-Training Attenuates Alzheimer's Disease-Related Pathology in a Transgenic Rat Model of Alzheimer's Disease. Geroscience. 2022 Jun;44(3):1457-1477
- Yang L, Wu C, Parker E, Li Y, Tucker L, Brann D, Lin H, Zhang Q. Non-invasive photobiomodulation treatment in an Alzheimer disease-like transgenic rat model. Theranostics. 2022 Feb 14;12(5):2205-2231.
- Wang J, Zhang Q, Lu Y, Dong Y, Dhandapani KM, Brann D, Yu R. Ganglioside GD3 is Up-regulated in Microglia and Regulates Phagocytosis Following Global Cerebral Ischemia. J Neurochem. 2021 Aug;158(3):737-752.
- Yang L, Wu C, Tucker L, Xu Pei, Zhang Q. Photobiomodulation Therapy Attenuates Anxious-Depressive-Like Behavior in Alzheimer Rat. J Alzheimers Dis. 2021;83(4):1415-1429.
- Li Y, Dong Y, Yang LD, Tucker L, Yang B, Zong XM, Hamblin M, Zhang Q. Transcranial photobiomodulation prevents PTSD-like comorbidities in rats experiencing underwater trauma. Translational Psychiatry. 2021 May 5;11(1):270.
- Li Y, Dong Y, Yang LD, Tucker L, Zong XM, Brann D, Hamblin M, Vazdarjanova A, Zhang Q. Photobiomodulation prevents PTSD-like memory impairments in rats. Molecular Psychiatry. 2021 Nov;26(11):6666-6679.
- Tucker L, Li Y, Zhang Q. Treating Posttraumatic Stress Disorder: A Timely Update on Therapeutic Strategies. Journal of Psychology and Psychotherapy Research, 2020, 7, 107-116.
- Yang L, Dong Y, Wu C, Youngblood H, Li Y, Zong X, Li L, Xu T, Zhang Q. Effects of prenatal photobiomodulation treatment on neonatal hypoxic ischemia in rat offspring. Theranostics. 2021 Jan 1;11(3):1269-1294.
- Zong X, Li Y, Liu C, Qi W, Han D, Tucker L, Hu S, Yan X, Zhang Q. Theta-burst Transcranial Magnetic Stimulation Promotes Stroke Recovery by vascular Protection and Neovascularization. Theranostics. 2020 Oct 26;10(26):12090-12110.
- Lu Y, Sareddy GR, Wang J, Zhang Q, Tang FL, Pratap UP, Tekmal RR, Vadlamudi RK, Brann DW. Neuron-Derived Estrogen Is Critical for Astrocyte Activation and Neuroprotection of the Ischemic Brain. J Neurosci. 2020 Sep 16;40(38):7355-7374.
- Yang L, Youngblood H, Wu C, Zhang Q. Mitochondria as a Target for Neuroprotection: Role of Methylene Blue and Photobiomodulation. Translational Neurodegeneration. 2020 Jun 1;9(1):19.
- Zhang Q, Wang RM, Khan MM, Mahesh VB, Brann DW*. Role of Dickoff-1 (DKK-1), an Antagonist of the WNT-β-Catenin Signaling Pathway, in Estrogen-Induced Neuroprotection and Attenuation of Tau Phosphorylation. Journal of Neuroscience, 2008 Aug 20; 28(34):8430-41. (Highlighted in “This Week in The Journal”, J. Neurosci. 28(34):i, 2008)
- Brann D, Raz L, Wang R, Vadlamudi R, Zhang QG. Estrogen signaling and neuroprotection in cerebral ischemia. J Neuroendocrinol. 2012 Jan;24(1):34-47.
- Zhang Q, Han D, Wang RM, Dong Y, Yang F, Vadlamudi RK, Brann DW. C terminus of Hsc70-interacting protein (CHIP)-mediated degradation of hippocampal estrogen receptor-{alpha} and the critical period hypothesis of estrogen neuroprotection. Proc Natl Acad Sci USA 2011 Aug 30;108(35):E617-24. Commentary: Morrison JH. A mechanism emerges for the critical period hypothesis for estrogen treatment. Proc Natl Acad Sci USA. 2011 Aug 19. PMID: 21856953
- Zhang Q, Raz L, Wang R, Han D, De Sevilla L, Yang F, Vadlamudi RK, Brann DW. Estrogen attenuates ischemic oxidative damage via an estrogen receptor alpha-mediated inhibition of NADPH oxidase activation. Journal of Neuroscience, 2009 Nov 4;29(44):13823-36.
- Sareddy GR, Zhang Q (Co-first author), Wang R, Scott E, Zou Y, O'Connor J, Chen Y, Dong Y, Vadlamudi RK, Brann DW*. Proline-, Glutamic Acid-, and Leucine-Rich Protein 1 (PELP1) Mediates Estrogen Rapid Signaling and Neuroprotection in the Brain. Proc Natl Acad Sci USA 2015 Nov 16, E6673–E6682.
- Jiang P, Chen C, Wang R, Chechneva OV, Chung SH, Rao MS, Pleasure DE, Liu Y, Zhang Q#, Deng W#. hESC-derived Olig2+ progenitors generate a subtype of astroglia with protective effects against ischaemic brain injury. Nat Commun. 2013 July;4:2196. #Co-director.
- Zhang QG, Wang R, Scott E, Han D, Yan, D, Tu J, Yang F, Sareddy GR, Vadlamudi RK, Brann DW. Hypersensitivity of the hippocampal CA3 region to stress-induced neurodegeneration and amyloidogenesis in a rat model of surgical menopause. Brain. 2013 May;136(Pt 5):1432-45.
- Zhang QG, Wang R, Tang H, Dong Y, Chan A, Sareddy GR, Vadlamudi RK, Brann DW. Brain-Derived Estrogen Exerts Anti-inflammatory and Neuroprotective Actions in the Rat Hippocampus. Mol Cell Endocrinol. 2014 May 25;389(1-2):84-91
Complete List of my Published Work:
Google Scholar: https://scholar.google.com/citations?user=kfE70KUAAAAJ&hl=en
NIH My Bibliography: https://www.ncbi.nlm.nih.gov/myncbi/1hIWpPFU5Sckv/bibliography/public
Team
Quan-guang Zhang, MS, PhD
Principal investigator (PI)
Department of Neurology, LSU Health Shreveport
BRI F7-22 (O), F7-35 (L), 1501 Kings Hwy, Shreveport, LA 71103
E-mail: quanguang.zhang@lsuhs.edu
Office phone: (318) 675-8289
Xiaohui Ma, MS, MD
Project manager for Institute for Cerebrovascular and Neuroregeneration Research (ICNR)
Department of Neurology, LSU Health Shreveport
BRI F7-35 (L), 1501 Kings Hwy, Shreveport, LA 71103
E-mail: xiaohui.ma@lsuhs.edu
Office phone: (318) 675-8290
Xiaohui Ma collaborates with the business manager and administrator affiliated with the Department of Neurology, working closely with the ICNR director, faculty, and staff. In this capacity, Xiaohui Ma supervises the daily operations of the institute and plays an active role in achieving its mission and overarching objectives. As Project Manager, responsibilities include overseeing intramural and extramural grants and fellowships through documentation, tracking, and review, fostering collaboration between institute staff and external entities, and supporting all faculty/staff in attaining both personal and institute-related goals.
Yu Feng, MS, PhD
Postdoctoral Fellow
Department of Neurology, LSU Health Shreveport
E-mail: yu.feng@lsuhs.edu
Areas of Specialty
Photobiomodulation; Exercise traning; Stroke; Hypoxic ischemic encephalopathy (HIE); Focal (stroke) and global (cardiac arrest) cerebral ischemia.
Biography
Yu Feng earned her PhD from Shanghai University of Sport in China, focusing on the impact of exercise and sex steroids on cognition. In 2022, she joined LSU Health Shreveport for her Postdoctoral research. Her ongoing research involves utilizing cellular and molecular approaches to delve into the mechanisms of non-invasive therapy for neurodegenerative diseases. Furthermore, she is investigating the role of steroids in regulating the effects of non-invasive therapy.
Selected Publications
Feng Y, Huang Z, et al. Activation of Testosterone-Androgen Receptor Mediates Cerebrovascular Protection by Photobiomodulation Treatment in Photothrombosis-induced Stroke Rats. CNS Neurosci Ther. 2024 Jan. In press.
Feng Y, Yang L, et al. Photobiomodulation treatment inhibits neurotoxic astrocytic polarization and protects neurons in in vitro and in vivo stroke models. Neurochem Int. 2023 Jan;162:105464.
Zhihai Huang, PhD Student
Department of Pharmacology, Toxicology & Neuroscience;
Neurology at LSU Health Shreveport
Email: zhihai.huang@lsuhs.edu
Areas of Specialty
Traumatic Brain Injury (TBI); Alzheimer’s Disease (AD); Photobiomodulation (PBM); Psychological Disorders; Physical Exercise.
Biography
Zhihai is a PhD student in the Department of Pharmacology, Toxicology & Neuroscience at LSU Health Shreveport. His research focuses on the pathophysiology of traumatic brain injury (TBI) and Alzheimer's disease. Specifically, he aims to identify novel targets for mitigating secondary injury following TBI and investigates the peripheral pathophysiology of Alzheimer's disease.
Zhihai is also interested in exploring the preventive and therapeutic effects of photobiomodulation and physical exercise on various psychological and neurological disorders. He is dedicated to translating scientific findings into practical applications in clinical settings.
Selected Publications
Huang Z, Jordan J. D., Zhang Q. Early Life Adversity as a Risk Factor for Cognitive Impairment and Alzheimer's Disease. Translational Neurodegeneration. 2023 May 12;12(1):25.
Huang Z, Jordan J. D., Zhang Q. Myelin pathology in Alzheimer's disease: potential therapeutic opportunities. Aging and Disease. 2023 Jul 24. doi: 10.14336/AD.2023.0628. Online ahead of print. PMID: 37548935
Huang Z, Zhang Y, et al. Photobiomodulation attenuates oligodendrocyte dysfunction and prevents adverse neurological consequences in a rat model of early life adversity. Theranostics 2023; 13(3): 913-930.
William C. Carr
Research Associate
(Neurology, Research Associate, 2020 - current)
Email: william.carr@lsuhs.edu
Positions
Post-doctoral Fellows and Graduate Students
We are happy to share the opportunity to participate in our research. If you want to learn and advance, you are welcomed to apply. You can send your CV at qzh001@lsuhs.edu.
Extramural Funding
Contact
Contact Us
LSU Health Shreveport
Department of Neurology
1501 Kings Hwy
Shreveport, LA 71103
Email: qzh001@lsuhs.edu
Office: (318) 675-8290
